See more : Cell Source, Inc. (CLCS) Income Statement Analysis – Financial Results
Complete financial analysis of Lotus Pharmaceuticals, Inc. (LTUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lotus Pharmaceuticals, Inc., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Millennium Food Tech Limited Partnership (MIFT.TA) Income Statement Analysis – Financial Results
- Letong Chemical Co.,LTD (002319.SZ) Income Statement Analysis – Financial Results
- HKScan Oyj (0ISM.L) Income Statement Analysis – Financial Results
- JAKS Resources Berhad (JAKS.KL) Income Statement Analysis – Financial Results
- Direct Communication Solutions, Inc. (DCSX) Income Statement Analysis – Financial Results
Lotus Pharmaceuticals, Inc. (LTUS)
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 72.70M | 57.82M | 73.80M | 56.87M | 36.21M | 134.35K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.92M | 25.35M | 40.44M | 33.68M | 26.52M | 61.47K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.78M | 32.47M | 33.36M | 23.19M | 9.68M | 72.88K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 54.72% | 56.15% | 45.21% | 40.78% | 26.75% | 54.24% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.55K | 0.00 | 1.20M | 2.41M | 387.34K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.02M | 3.39M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.39M | 8.04M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.81K | 21.11K | 30.41K | 6.28K | 0.00 | 18.41M | 11.43M | 17.09M | 9.47M | 4.87M | 224.14K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -21.83K | -3.44M | -26.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 18.81K | 21.11K | 30.41K | 6.28K | -21.83K | 18.50M | 11.43M | 18.29M | 11.89M | 5.26M | 224.14K |
| Cost & Expenses | 18.81K | 21.11K | 30.41K | 6.28K | -21.83K | 51.41M | 36.79M | 58.73M | 45.56M | 31.78M | 285.61K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.14K | 48.52K | 12.63K | 102.15K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 612.63K | 2.15M | 1.93M | 2.04M | 325.82K | 3.06K |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | 2.25M | 1.99M | 1.16M | 2.23M | 567.47K | 3.87K |
| EBITDA | -18.81K | -21.11K | -30.41K | -6.28K | -21.83K | 17.56M | 21.35M | 16.59M | 13.54M | 4.99M | -147.40K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 32.38% | 39.90% | 22.48% | 20.56% | 13.79% | -109.71% |
| Operating Income | -18.81K | -21.11K | -30.41K | -6.28K | -21.83K | 14.52M | 19.32M | 15.07M | 11.31M | 4.43M | -151.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 19.98% | 33.41% | 20.42% | 19.88% | 12.23% | -112.59% |
| Total Other Income/Expenses | -2.00 | 2.00 | -3.00 | -3.00 | 0.00 | -6.64M | -2.52M | -2.28M | -91.17K | -325.82K | 1.99M |
| Income Before Tax | -18.81K | -21.11K | -30.41K | -6.28K | 0.00 | 14.65M | 16.80M | 12.79M | 11.22M | 4.10M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.15% | 29.06% | 17.33% | 19.72% | 11.33% | 0.00% |
| Income Tax Expense | -167.90K | -228.49K | -236.56K | -206.30K | 21.83K | 220.29K | 368.68K | 2.28M | 91.17K | 0.00 | 3.06K |
| Net Income | -18.81K | -21.11K | -30.41K | -6.28K | -21.83K | 14.42M | 16.43M | 12.79M | 11.22M | 4.10M | -154.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 19.84% | 28.42% | 17.33% | 19.72% | 11.33% | -114.87% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.37 | 0.60 | 0.54 | 0.20 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.33 | 0.54 | 0.52 | 0.20 | -0.01 |
| Weighted Avg Shares Out | 2.69B | 2.69B | 2.94B | 2.94B | 2.79B | 52.36M | 44.21M | 21.15M | 20.71M | 20.18M | 20.02M |
| Weighted Avg Shares Out (Dil) | 2.69B | 2.69B | 2.94B | 2.94B | 2.79B | 53.99M | 50.05M | 24.03M | 21.93M | 20.18M | 20.02M |
No news found for: LTUS
Source: https://incomestatements.info
Category: Stock Reports